10x Genomics TXG
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 12th percentile, 5-year average -44.0x
Near the top of its 5-year range · 87th percentile, 5-year average 5.8x
#4892 of 5331 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 84th percentile, 5-year average 8.4x
#4581 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 9.13 | – | 5.84 | 87% (pricier than usual) | #4892 of 5331 (1 = cheapest) |
| PE | -111.90 | -82.26 | -43.99 | 12% (cheaper than usual) | – |
| PS | 12.37 | 11.05 | 8.42 | 84% (pricier than usual) | #4581 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on TXG.
Sign in to join the discussion.